Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$445.21 USD
+4.57 (1.04%)
Updated May 17, 2024 04:00 PM ET
After-Market: $445.23 +0.02 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VRTX 445.21 +4.57(1.04%)
Will VRTX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRTX
Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth Stock
Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth Stock
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
Other News for VRTX
Novo Nordisk, J&J lead R&D rankings in big pharma: report
Jennifer Schneider Elected to Vertex Board of Directors
Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades'
Tracking Tweedy Browne Portfolio - Q1 2024 Update
Vertex Pharmaceuticals Takes Over #81 Spot From Nike